WHO-GMP Certified Commercial Pack · Product Code: AKP-170
Glimepiride 1 mg, Metformin 500 mg & Pioglitazone 15 mg Tablets
Formulation Overview: Three-pathway fixed-dose antidiabetic tablet combining 1 mg glimepiride, 500 mg metformin, and 15 mg pioglitazone to simultaneously target insulin secretion, hepatic output, and peripheral resistance. Formulated with Glimepiride 1 mg + Metformin 500 mg + Pioglitazone 15 mg (1 mg + 500 mg + 15 mg) in Triple-Combination Film-Coated Tablets dosage form under Anti-Diabetic Medication, manufactured to IP / BP / USP Compendial standards and supplied in 10 x 10 Alu-Alu / Blister Pack with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
| Item Code (SKU) | AKP-170 |
|---|---|
| Catalog Reference | AKP-170 · SN 170 |
| Therapeutic Sector | Anti-Diabetic Medication |
| Dosage Form | Triple-Combination Film-Coated Tablets |
| Active Ingredient | Glimepiride 1 mg + Metformin 500 mg + Pioglitazone 15 mg |
| Strength / Purity | 1 mg + 500 mg + 15 mg |
| Clinical Indication | Refractory Type 2 diabetes mellitus requiring comprehensive fasting and postprandial triple glycemic control |
| Specification Standard | IP / BP / USP Compendial |
| Packaging Format | 10 x 10 Alu-Alu / Blister Pack |
| Shelf Life | 24–36 Months |
| Storage Conditions | Store below 25°C in a dry place, protect from light and moisture |
| Minimum Order Quantity | 1000 Packs |
| Regulatory / Analytical Docs | Full eCTD / ACTD Modules 1–5 + Zone IVb Stability Available |
| African & Global NRA Readiness | NAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA |
| Stock Availability | In Stock · Immediate Commercial Dispatch |
| Supply Status | Commercial Export Ready |